Clinical Trial Update: AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial compares AK112 (ivonescimab) plus FOLFIRI to bevacizumab plus FOLFIRI as second-line therapy for MSS/pMMR metastatic colorectal cancer; the stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• AK112
• Bevacizumab (bevacizumab)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Colorectal Cancer, Ivonescimab | Phase 2 | Status: NOT_YET_RECRUITING